What is Pulmatrix?
Pulmatrix is a specialized biopharmaceutical entity focused on the development of inhaled therapies designed to treat serious respiratory and systemic diseases. At the core of its operations is the patented iSPERSE technology, an engineered dry powder platform that optimizes drug delivery to the lungs. This platform is currently being leveraged to address high-unmet-need conditions, including Chronic Obstructive Pulmonary Disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and various neurologic disorders such as acute migraine. By prioritizing localized delivery, the company aims to enhance patient outcomes and reduce the side-effect profiles typically associated with systemic administration.
How much funding has Pulmatrix raised?
Pulmatrix has raised a total of $157.3M across 15 funding rounds:
Debt
$20.5M
Share Placement
$10M
Stock Offering
$9.7M
Stock Offering
$15.9M
Stock Offering
$3M
Multiple Rounds
$20.3M
Stock Offering
$8M
Stock/Share Issuance
$1M
Debt (2013): $20.5M with participation from Undisclosed
Share Placement (2015): $10M led by ARCH Ventures, 5AM Ventures, Polaris Partners, and Altitude Life Science Ventures
Stock Issuance/Offering (2017): $9.7M supported by Undisclosed
Stock Issuance/Offering (2018): $15.9M featuring Undisclosed
Stock Issuance/Offering (2018): $3M backed by Undisclosed
Stock Issuance/Offering (2019): $1.2M with participation from Undisclosed
Stock Issuance/Offering (2019): $2.5M led by Undisclosed
Stock Issuance/Offering (2019): $16.6M supported by Undisclosed
Stock Issuance/Offering (2020): $8M featuring Undisclosed
Stock/Share Issuance (2026): $1M, investors not publicly disclosed
Key Investors in Pulmatrix
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching, advice, and resources for growth.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
What's next for Pulmatrix?
With the recent capital injection, Pulmatrix is positioned to accelerate its clinical trial milestones and further validate the efficacy of its iSPERSE-based product candidates. The strategic focus remains on advancing its pipeline through late-stage clinical trials and exploring potential commercialization pathways for its lead assets. As the company matures, the emphasis will likely shift toward scaling manufacturing capabilities and strengthening its intellectual property portfolio to maintain its competitive edge in the inhaled therapeutics market. Continued engagement with institutional partners will be vital as the firm navigates the regulatory complexities inherent in bringing novel pulmonary treatments to market.
See full Pulmatrix company page
